Deals Report: Pfizer collaborates with second Flagship company, three China deals, and more
BioCentury’s weekly deals analysis
Deal highlights of the last seven days include the latest step in an ongoing relationship between Pfizer and Flagship; three deals covering rights in China to programs in cancer and cardiovascular disease; and a partnership between Bayer and NextRNA to target long non-coding RNAs.
As a part of its 2023 partnership with Flagship Pioneering Inc. to develop up to 10 single-asset programs, Pfizer Inc. (NYSE:PFE) is partnering with Flagship-founded Quotient Therapeutics Inc. The pair will focus on discovering targets for cardiovascular and renal disease therapies using Quotient’s genomics platform for identifying somatic mutations in diseased patient tissue. The agreement marks the second under Pfizer-Flagship partnership, following the announcement in June of a collaboration with ProFound Therapeutics Inc. to discover first-in-class protein therapies for obesity...